Welcome to our dedicated page for DECOY THERAPEUTICS news (Ticker: DCOY), a resource for investors and traders seeking the latest updates and insights on DECOY THERAPEUTICS stock.
Decoy Therapeutics Inc. develops preclinical peptide conjugate therapeutics built around Designable Multi-Antivirals, or D-MAVs, and its proprietary IMP3ACT platform. Company news centers on AI-enabled peptide design, rapid synthesis and manufacturing, respiratory-virus programs, and scientific presentations tied to pan-coronavirus and broad antiviral discovery efforts.
Recurring updates also include computational biology collaborations, non-dilutive program support, investor communications, capital-market actions, and Nasdaq listing-compliance matters. The company's public updates frame Decoy as a preclinical biotechnology issuer focused on respiratory viruses, with earlier company materials also referencing GI cancer pipeline work.
Decoy Therapeutics (NASDAQ: DCOY) announced on Feb 11, 2026 that it joined the Webull Corporate Connect Service platform to provide an additional communication channel for shareholders and investors. The company said the portal will distribute corporate news, earnings reports, product updates, presentations and notifications to improve transparency and engagement.
Decoy Therapeutics (Nasdaq: DCOY) will present at the Corporate Connect Webinar Series hosted by Webull Financial on Tuesday, February 10, 2026 at 1:20 PM EST.
CEO Rick Pierce will give a brief corporate overview and highlight the company's new class of antiviral peptide conjugate therapeutics that target multiple viral pathogens.
Decoy Therapeutics (Nasdaq: DCOY) participated in a virtual investor "What This Means" segment on Feb. 4, 2026, detailing its Global Access Commitment Agreement (GACA) with the Gates Foundation.
The company described plans to develop a flexible, scalable manufacturing platform for peptide-conjugate antivirals using its IMP3ACT™ technology, validated by an intranasal pan-coronavirus fusion inhibitor funded under the same Gates Foundation grant.
Decoy Therapeutics (Nasdaq: DCOY) announced a Global Access Commitment Agreement with the Gates Foundation to fund development of a globally accessible, scalable peptide-conjugate manufacturing platform for antiviral therapeutics. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor and built with U.S. and European contract manufacturers to enable rapid scale-up on standard peptide-synthesis machinery. Decoy expects to advance its lead pan-coronavirus antiviral to an IND filing within 12 months and progress programs for broad-acting flu/COVID-19/RSV antivirals and a peptide drug conjugate for GI cancers.